Major Depressive Disorder

Here are 5 rape myths perpetuated in our culture, in law enforcement and the military, and in medicine and mental health.

Samuel T. Wilkinson, MD, discusses the risks and benefits, as well as the challenges of clinical implementation of esketamine, for treatment-resistant depression.

Mounting evidence shows the endogenous opioid system is a potential therapeutic target for mood disorders, yet questions remain.

Investigators used machine learning to derive a unique electroencephalographic pattern or “signature” that appears to predict response to antidepressants vs. placebo.

Regardless of whatever short-term benefit patients perceive from cannabis, the evidence points clearly to an association between usage and worsening course of bipolar disorder over time.

Is there special guidance for APA members regarding COVID-19 and their practices/patients? What resources are available?

The US Food and Drug Administration is working diligently to provide the public with information to keep consumers well and safe. From hand sanitizers to testing to food safety, this slideshow presents the latest developments.

How will the coronavirus pandemic impact psychiatry as a field? Are there any neuropsychiatric symptoms associated with the COVID-19 virus? Those questions answered in this video.

Psychiatric Times has collected information to answer your most pressing questions, including how to prepare your office and staff, resources for patients, and information you need to implement telepsychiatry.

Experts discuss the rationale and history of L-methylfolate use in patients, and then shares three cases that collectively suggest L-methylfolate may contribute to agitation and mania.

What are the benefits of using LAI antipsychotics? What are the major obstacles to adherence? Those questions and more in this podcast.

In this time of uncertainty, sometimes we need to refocus on what’s important. Take a deep breath, and then tell us, what do you think of when you see this image? An image IQ.

Patients with difficult conditions such as delusional parasitosis tend to resist the notion that a psychiatric problem underlies their symptoms.

Psychiatric Times wants to know how the pandemic is impacting your practice and your lives.

Psychiatrists must have a basic understanding of the pathophysiology of coronaviruses in order to be able to accurately explain and discuss those issues with their patients, especially as mental health ramifications are expected.

There are people who insist the one-hour change causes havoc on their systems and schedules. Is there any scientific foundation to this claim? Let us examine some common questions, concerns, and myths.

Chronotherapy presents a unique tool to add to the armamentarium of available modalities for management of non-seasonal depression. Clinicians should be familiar with its application and be able to implement it in recalcitrant sufferers.

The FDA accepts a New Drug Application for novel antidepressant.

Although the current generation of antidepressants extends back to the late 1980s, efforts to describe the dose-response relationship for treatment of major depressive disorder continue. More in this research update.

Depression, suicidal ideation, self-harming behaviors, and anxiety, as well as lower reaction time and cognitive decline, were found in patients with celiac disease, according to a recent study

How effective is deep brain stimulation for treatment-resistant depression? Take the quiz.

The goals of psychotherapy education in medical school should be based on these seven ideals.

We often hear about seasonal affective disorder, but we don’t talk much about “winter woes.” Amaryllis offers something for everyone, for it encourages celebrations on many occasions, over as many months.

A diminished interest in psychotherapeutic interventions runs the risk of missing patients' emotional, social, and practical needs (including medication-modifiable symptoms) and, thus, less clinically responsible care.

This research update underscores the need to be well versed in the data in order to have meaningful conversations with our patients who are cannabis users or contemplate use.

Although multiple interventions exist for major depressive disorder (MDD), only partial response is achieved in many patients and recurrence is common. Combining medication and psychotherapy may enable more effective treatment of MDD.

The author shares some thoughts on the current state of biopsychosocial model as well as the new proposed reinterpretation of BPS as a theory of causality.

A reformulated biopsychosocial paradigm can be clinically useful. How? Keep reading.

Many patients can benefit from herbs with gentler action, fewer adverse effects, and some health benefits beyond their antidepressant effects.